Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GX-I7 plus bevacizumab in recurrent glioblastoma
KCT0006561Phase 2Recruiting
- Sponsor
- Genexine
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of efineptakin alfa, bevacizumab in glioblastoma (GBM), sponsored by Genexine. Started Jan 2022; status: recruiting.
02
Drugs
efineptakin alfabevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on KCT0006561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006561.